Navigation Links
InterMune to Release Third Quarter Financial Results on October 28
Date:10/21/2010

BRISBANE, Calif., Oct. 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it will release third quarter 2010 financial results on Thursday, October 28, 2010 at 4:00 p.m. Eastern time.  A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

To access the live teleconference, dial 888-567-5125 (U.S.) or 706-643-9223 (international), conference ID# 20132776.  To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.  

A replay of the webcast and teleconference will be available approximately three hours after the call.  The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 20132776.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.  InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections.  The pulmonology portfolio includes pirfenidone for which InterMune has completed a Phase 3 program in patients with IPF (CAPACITY).  A Marketing Authorization Application (MAA) for pirfenidone is under review by the European Medicines Agency (EMA).  The hepatology portfolio includes next-generation HCV protease inhibitor and NS5A research programs.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
3. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
4. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
5. InterMune to Release Third Quarter 2008 Financial Results on November 6
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. InterMune to Present at J.P. Morgan Healthcare Conference
9. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
10. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... DUBLIN , Mar. 04, 2015 Research ... announced the addition of Jain PharmaBiotech,s new report ... to their offering. This report ... a characteristic that can be objectively measured and ... pathogenic processes as well as pharmacological responses to ...
(Date:3/4/2015)... 4, 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) (the ... a collaborative research program with Emerald Logic, ... Collective Evolution Technology (FACET), Emerald Logic analyzed ... obtained from each of 798 patients who ... trials ASSERT, SUSTAIN and ASSURE. The objective ...
(Date:3/4/2015)... 04, 2015 Proove Biosciences ... Medicine, is excited to announce the launch of ... Optimize the Management of Pain”. , The continuing ... for the next year. The focus of the ... recognize inadequate pain treatments, integrate appropriate pain management ...
(Date:3/4/2015)... Pa. , March 4, 2015 /PRNewswire/ ... services and technology provider, today announced that ... 10 countries convened at its annual European ... to discuss the use of ... challenges. BioClinica,s eClinical technologies include: the Microsoft ...
Breaking Biology Technology:Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3
... (NYSE: DGX ), the nation,s leading provider ... is scheduled to speak,at the Lehman Brothers Eleventh ... at The Loews Miami Beach Hotel, Miami, Florida.,The ... 9:00 a.m.,Eastern Time., The presentation will be ...
... DIEGO, March 14 NuVasive, Inc. (Nasdaq:,NUVA), a medical ... treatments for the spine, announced today,that Kevin O,Boyle, Executive ... at the Lehman Brothers Eleventh Annual Global,Healthcare Conference at ... on,Wednesday, March 19, 2008 at 10:15 a.m. ET., ...
... webcast live and archived on Company,s web site, ... (Nasdaq: MBRK ), a pharmaceutical company focused ... Dr. Edward M. Rudnic, MiddleBrook president and CEO, ... 2008, at 4:45 p.m.,Eastern Time., The presentation ...
Cached Biology Technology:Quest Diagnostics to Speak at Lehman Brothers 11th Annual Global Healthcare Conference 2NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference 2NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference 3MiddleBrook Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference 2
(Date:2/5/2015)...  It is gratifying to see that the Obama ... science as a means to better understand human biology, ... was honored to participate in today,s White House event ... Since the 1980s my teams have been ... sequenced genome of a free living organism, the first ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ... in general the State of Washington,s ... a new enrollment and central issuance system for driver,s licenses ... The project planning and development will start in January ...
(Date:1/22/2015)... 13, 2015 Technology Showcase, Hall E -   EyeLock ... today announced it will showcase its EyeLock ID technology integrated ... Department of Energy,s Oak Ridge National Laboratory (ORNL) ... EyeLock,s iris identity authentication technology is being used to validate ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Valid USA Signs Contract For Washington Driver's License Issuance 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... Researchers with Lawrence Berkeley National Laboratory (Berkeley Lab) ... U.S Department of Homeland Security (DHS) in conjunction ... determine how airborne contaminants would spread if released ... is now underway and runs from December 5-11, ...
... Though they remain a leading killer, heart attacks ... diagnosed following initial onset of symptoms. In a study ... , researchers have identified cardiac myosin-binding protein C (cMyBP-C) ... one that may be particularly valuable for mild attacks ...
... Kingdom, December, 2009 Newly published research, by investigators, ... in the journal Stem Cells reported the ... Cell Deficiency" (LSCD) using the patients, own stem cells ... LSCD is a painful, blinding disease that ...
Cached Biology News:Berkeley Lab researchers participate in Homeland Security study of subway airflow 2Potential new heart attack biomarker uncovered 2Successful stem cell therapy for treatment of eye disease 2
... 0-10 psi precision pressure regulator and pressurized ... Faster liquid-switching Steady flow rate ... delivery Can be added to any ... Scientific, any third-party manufacturer, even homemade. Connect to ...
...
Chicken polyclonal to UCK2 ( Abpromise for all tested applications). Antigen: Full length protein, corresponding to amino acids 1-261 of Human UCK2 Entrez Gene ID: 7371 Swiss Protein ID: ...
... (rEK) is a highly purified preparation of ... serine protease which recognizes the identical cleavage ... has similar enzymatic activity. Novagen&'s enzyme is ... purified to yield the highest activity available, ...
Biology Products: